On Dec. 21, 2020, Novan announced it had entered into a Master Services Agreement (MSA) with Catalent, which will include support of chemistry, manufacturing and control (CMC) activities and development of an intranasal formulation of berdazimer sodium for use in the Companyﾒs coronavirus (COVID-19) program.